A community-based salt substitution programme in Peru lowered blood pressure (BP) and reduced the cumulative probability of developing hypertension, according to results presented at the European Society of Cardiology (ESC) Congress 2019 and World Congress of Cardiology (WCC) 2019.
The angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan has demonstrated a modest effect vs valsartan alone on hospitalization and death in patients with heart failure with preserved ejection fraction (HFpEF), with results suggesting a greater benefit in women and patients with borderline low left ventricular EF (LVEF).
The sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin significantly reduces the risk of death and hospitalization in patients with heart failure (HF) with reduced ejection fraction (rEF) regardless of whether they have type 2 diabetes mellitus (T2DM), the DAPA-HF trial has shown.
In patients with type 2 diabetes mellitus (T2DM) and stable coronary artery disease (CAD) without prior MI or stroke, ticagrelor plus low-dose aspirin significantly reduces ischaemic cardiovascular (CV) events vs aspirin alone, at the expense of increased major bleeding, with a favourable net clinical benefit observed in those with a history of percutaneous coronary intervention (PCI).
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.